4D Molecular Therapeutics FDMT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$68.76M-43.3% | —— | -$56.88M-29.7% | -$54.66M-56.4% | -$47.97M-48.1% | ||
| $1.27M+20.7% | $1.22M+10.9% | $1.26M+6.0% | $1.17M-2.3% | $1.05M-10.4% | ||
| $4.45M-36.3% | $5.55M-26.7% | $4.52M-30.4% | $4.96M-18.4% | $6.99M+16.9% | ||
| $3.53M+1,603% | $4.3M+194% | —— | $4.55M+679% | -$235K-133% | ||
| -$4.12M-78.3% | $2.37M— | $4.98M-38.5% | $3.11M-2.0% | -$2.31M+3.2% | ||
| $670K-75.9% | —— | —— | $2.35M+51.6% | $2.78M+3,061% | ||
| $1.38M+9,957% | -$90K— | -$90K— | -$15K— | -$14K-118% | ||
| $786K+11.8% | $764K+11.0% | $742K+44.6% | $722K+67.9% | $703K+67.0% | ||
| -$878K-16.4% | -$850K-274% | -$814K-99.5% | -$775K-50.5% | -$754K-50.5% | ||
| -$68.13M-42.6% | —— | -$46.5M-58.2% | -$43.38M-43.4% | -$47.76M-64.2% | ||
| $0-100% | —— | —— | $66K-81.1% | $631K-11.1% | ||
| $68.89M+116% | -$128.85M— | $17.78M— | -$13.85M+81.2% | $31.95M+112% | ||
| —— | —— | —— | —— | —— | ||
| $11.48M— | $111.98M+18,533% | $116K-79.6% | $862K-95.0% | $0-100% | ||
| $12.25M+177% | —— | -$28.6M-1,779% | -$56.37M+34.9% | -$15.81M-160% | ||
| $1.13M-10.5% | $1.15M-38.0% | $1.15M-48.5% | $1.17M-50.1% | $1.27M+67.4% | ||
| $12K+114% | —— | —— | —— | -$88K— | ||
| -$878K-16.4% | -$850K-274% | -$814K-99.5% | -$775K-50.5% | -$754K-50.5% | ||
| $3.99M+272% | $3.17M+166% | -$2.75M— | —— | $1.07M-18.8% | ||
| $786K+11.8% | $764K+11.0% | $742K+44.6% | $722K+67.9% | $703K+67.0% | ||
| -$11K-102% | —— | —— | —— | $631K— | ||
| $1.67M— | —— | —— | —— | $0— | ||
| —— | $1.88M— | $1.88M— | $1.88M— | $1.88M— | ||
| —— | $246K-78.5% | $246K-78.5% | $246K-78.5% | $246K-78.5% | ||
| $0-100% | —— | —— | —— | $140K— | ||
| $1.38M+9,957% | -$90K— | -$90K— | -$15K— | -$14K-118% | ||
| -$878K-16.4% | -$850K-274% | -$814K-99.5% | -$775K-50.5% | -$754K-50.5% | ||
| $98K— | —— | —— | —— | $0— | ||
| —— | $76.75K— | $76.75K— | $76.75K— | $76.75K— | ||
| -$68.13M-40.8% | —— | -$46.41M-48.9% | -$43.44M-42.0% | -$48.39M-62.4% | ||
| -$68.13M-40.8% | —— | -$46.41M-48.9% | -$43.44M-42.0% | -$48.39M-62.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does 4D Molecular Therapeutics generate?
- 4D Molecular Therapeutics (FDMT) generated -$205.8M in operating cash flow over the trailing twelve months.
- What is 4D Molecular Therapeutics's free cash flow?
- After $1.6M of capital expenditures, 4D Molecular Therapeutics's free cash flow was -$206.4M over the trailing twelve months, down 49.1% year over year.
- Where does 4D Molecular Therapeutics's cash flow data come from?
- Every line is extracted from 4D Molecular Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
